Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Gattermann, N; Finelli, C; Porta, MD; Fenaux, P; Ganser, A; Guerci-Bresler, A; Schmid, M; Taylor, K; Vassilieff, D; Habr, D; Domokos, G; Roubert, B; Rose, C; EPIC study investigators; Agaoglu, L; Alimena, G; Alonso, D; Ame, S; Angelucci, E; Businco, A; Arrizabalaga, B; Athanasiou-Metaxa, M; Augustson, B; Aydinok, Y; Baba, A; Baccarani, M; Beck, J; Beris, P; Beyne-Rauzy, O; Birgens, H; Bordessoule, D; Borgna-Pignatti, C; Bosly, A; Bouabdallah, K; Bowden, D; Bowen, D; Bron, D; Cappellini, MD; Capr...    »
 
Titel:
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 
Abstract:
The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was>2500ng/mL, approximately 50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS. 
Zeitschriftentitel:
Leuk Res 
Jahr:
2010 
Band / Volume:
34 
Heft / Issue:
Seitenangaben Beitrag:
1143-50 
Sprache:
eng 
Print-ISSN:
0145-2126 
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik